MX2023003754A - Formulacion farmaceutica para inhalador presurizado de dosis medidas. - Google Patents

Formulacion farmaceutica para inhalador presurizado de dosis medidas.

Info

Publication number
MX2023003754A
MX2023003754A MX2023003754A MX2023003754A MX2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A MX 2023003754 A MX2023003754 A MX 2023003754A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
metered dose
dose inhaler
pressurised metered
pharmaceutical composition
Prior art date
Application number
MX2023003754A
Other languages
English (en)
Inventor
Sauro Bonelli
Diego Copelli
Francesca Usberti
Enrico Zambelli
Alberi Massimiliano Dagli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023003754A publication Critical patent/MX2023003754A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a una composición farmacéutica que comprende un agente de LABA, opcionalmente en combinación con otros ingredientes activos, una mezcla de por lo menos dos ácidos inorgánicos, un propelente y un cosolvente. La invención también proporciona una composición farmacéutica para el tratamiento de enfermedades respiratorias, tales como asma y EPOC.
MX2023003754A 2020-10-09 2021-10-08 Formulacion farmaceutica para inhalador presurizado de dosis medidas. MX2023003754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20201060 2020-10-09
PCT/EP2021/077827 WO2022074183A1 (en) 2020-10-09 2021-10-08 A pharmaceutical formulation for pressurised metered dose inhaler

Publications (1)

Publication Number Publication Date
MX2023003754A true MX2023003754A (es) 2023-04-24

Family

ID=72826742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003754A MX2023003754A (es) 2020-10-09 2021-10-08 Formulacion farmaceutica para inhalador presurizado de dosis medidas.

Country Status (13)

Country Link
US (1) US20230277451A1 (es)
EP (1) EP4225267A1 (es)
JP (1) JP2023546025A (es)
KR (1) KR20230084482A (es)
CN (1) CN116419749A (es)
AU (1) AU2021356146A1 (es)
CA (1) CA3193038A1 (es)
CL (1) CL2023000998A1 (es)
CO (1) CO2023004162A2 (es)
IL (1) IL301617A (es)
MX (1) MX2023003754A (es)
PE (1) PE20240629A1 (es)
WO (1) WO2022074183A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013262A1 (en) * 1992-12-09 1994-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
JP2007537170A (ja) * 2004-05-13 2007-12-20 チエシイ・ファルマセウテイシイ・エス・ペー・アー 化学的安定性が改良された薬用エーロゾル配合物製品
EP2515855B3 (en) 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
GB2593970A (en) * 2020-02-20 2021-10-13 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Also Published As

Publication number Publication date
PE20240629A1 (es) 2024-03-26
CN116419749A (zh) 2023-07-11
WO2022074183A1 (en) 2022-04-14
CA3193038A1 (en) 2022-04-14
EP4225267A1 (en) 2023-08-16
JP2023546025A (ja) 2023-11-01
US20230277451A1 (en) 2023-09-07
AU2021356146A1 (en) 2023-05-04
IL301617A (en) 2023-05-01
KR20230084482A (ko) 2023-06-13
CL2023000998A1 (es) 2023-11-24
CO2023004162A2 (es) 2023-04-17

Similar Documents

Publication Publication Date Title
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CA2474479A1 (en) Composition for inhalation
AR038641A1 (es) Formulacion superfina de formoterol
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
HRP20140550T1 (hr) Aerosolna formulacija za copd
WO2011076841A3 (en) Combination therapy for copd
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX2022009643A (es) Inhaladores dosificadores presurizados que comprenden una formulacion farmaceutica amortiguada.
JP2019528316A5 (es)
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
HRP20140818T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
JP2004529108A5 (es)
NZ600208A (en) Inhalation solutions
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
PE20240808A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
MX2022008440A (es) Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada.
WO2004103339A3 (en) Improved metered dose inhaler